Does the surgeon matter in the management of ovarian cancer? by Chan, K K
The survival of patients with ovarian cancer in the UK compares
poorly with other Western countries. A large part of this difference
must be due to the organization of treatment as well as the treat-
ment given to these patients. For example, Paclitaxel is still not
available to all patients with ovarian cancer in the UK, despite the
fact that it has been clearly demonstrated that the combination of
this drug with Cis-platinum is clearly superior to the combination
of platinum analogues with alkylating agents which was the
previous gold standard (Hawkins, 1998; Gore, 1998; Sandercock,
1998). The formal comparison of taxol-carboplatin with carbo-
platin (ICON3) is eagerly awaited (Hawkins, 1998; Sandercock,
1998; Gore, 1998). Although over 80% of patients with ovarian
cancer present with advanced disease, the quality of chemotherapy
treatment is not the sole factor in determining the success of treat-
ment. There is evidence to support the idea that the surgeon may
have an important role to play.
Junor et al (1994) showed an improved survival for patients
with ovarian cancer treated by a multidisciplinary team in
Scotland. In a national survey of ovarian cancer treated in the
USA, Nguyen et al (1993) showed a significantly better survival in
those patients operated on by gynaecologists compared with those
by general surgeons. Mayer et al (1992) showed a significant
improvement in survival for those patients with stage I and II
disease staged by a gynaecological oncologist when compared
with those patients staged by a non-oncologist. Five-year actuarial
and disease-free survival were 83 ± 7% and 76 ± 8% for those
staged by a gynaecological oncologist compared to 59 ± 11%
(P < 0.05) and 39 ± 11% (P < 0.03) for the group staged by a
non-oncologist.
The better results obtained by gynaecological oncologists and
those working in multidisciplinary teams are likely to be the result
of more careful staging and a stricter adherence to surgical guide-
lines. Sengupta’s audit of the surgical management of patients
referred to a regional oncology centre demonstrates the poor
compliance with management guidelines published by the
Standing Subcommittee on Cancer of the Standing Medical
Advisory Committee in July 1991 (Scott, 1991). These guidelines
have become known as the Scott Report4 and represent a balanced
view of the management of ovarian cancer at that time. The
majority of the patients (92%) were seen in the out-patient clinic
so the operations were elective, yet fewer than half the patients
underwent the recommended surgical procedures. Even the
recording of surgical details was poor; only in 75 out of 85 case
notes inspected was the initial incision recorded. The residual
disease status was only recorded in 45 cases despite the well-
known prognostic significance of this factor.
Staging is most important in those patients suspected to have
stage I disease. Faught et al5 showed the value of identifying true
stage IA or IB patients since these women require surgery only.
Schueler et al (1998) performed a comprehensive staging pro-
cedure on all their patients and found that 13 out of 45 patients
(29%) were upstaged due to the presence of microscopic disease.
The complication rate in secondary staging procedures was
significantly higher than in primary procedures (77% vs 23%)
(P < 0.05). In Sengupta’s series none of the 21 patients with
suspected stage I disease had a staging procedure that followed the
Scott Report guidelines fully. None of the women had any lymph
node biopsy. Petru et al (1994) found lymph node metastases in
nine out of 40 (23%) apparent stage I patients.
Sengupta’s audit revealed the varying standards of compliance
with the Calman–Hine Report’s (Department of Health, 1995)
recommendations. In one hospital a single consultant operated
on 11 patients, while in another seven consultants operated on
17 patients. The evidence shows that patients with ovarian cancer
benefit from undergoing their treatment in multidisciplinary teams
and specialized units. It also shows that the specialty of the
surgeon performing the initial laparotomy has a direct bearing
on the prognosis of the patient. The Calman–Hine Report was
published in 1995. It is high time that Health Authorities and
Health Purchasing Groups act to ensure that women with
suspected ovarian cancer are referred to gynaecological oncolo-
gists or those gynaecologists who have the interest and the
expertise to treat them correctly within a multidisciplinary setting.
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